Tyck till om SwePub Sök här!
onr:"swepub:oai:DiVA.org:uu-318840"
Search: onr:"swepub:oai:DiVA.org:uu-318840" > Current Status of R...
- 1 of 1
- Previous record
- Next record
- To hitlist
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
-
- Fani, Melpomeni (author)
- Division of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, Switzerland
-
- Peitl, Petra Kolenc (author)
- Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
-
- Velikyan, Irina, 1966- (author)
- Uppsala universitet,Radiologi,Preparativ läkemedelskemi
- (creator_code:org_t)
- 2017-03-15
- 2017
- English.
- In: Pharmaceuticals. - : MDPI AG. - 1424-8247. ; 10:1
- Research review (peer-reviewed)
Abstract
Subject headings
Close
- Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon-Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists. The purpose of this review is to present the current status and the most innovative strategies for the diagnosis and treatment (theranostics) of neuroendocrine neoplasms using a cadre of radiolabeled regulatory peptides targeting their receptors.
Keyword
- CCK2
- GIP
- GLP-1R
- exendin-4
- gastrin
- neuroendocrine neoplasms
- radiolabeled peptides
- somatostatin receptor antagonists
- theranostics
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
- Pharmaceuticals (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Fani, Melpomeni
- Peitl, Petra Kol ...
- Velikyan, Irina, ...
- Articles in the publication
- Pharmaceuticals
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
